SavedAdd your journal

Journals / Eurasian Journal of Medicine and Oncology / 2021 / Cilt: 5 - Sayı: 2

A Meta-Analysis of the Prognostic Value of AbnormallyExpressed lncRNAs and Correlation with ClinicopathologicalCharacteristics in Glioma

Ling CHEN
Hong SUN
Jiaxin LIU
Xiaowei MA
Li TAN
Yanli YAN
Shuai SHAO
Rui LIU
Hailin MA
BeiNa HUI
Linyan CHAI
Juan REN
Pages
144–156
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The highexpression of lncRNA was related to WHO staging (OR=0.31, 95%CI: 0.19-0.50, p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Abnormal expression of lncRNAs are involved in the occurrence and development of glioma.
📊
Key Findings & Data:Haz ard ratio (HR) and 95% confidence intervals (CI) were calculated in the analysis of prognostic indicators.
💡
Conclusion & Impact:The highexpression of lncRNA was related to WHO staging (OR=0.31, 95%CI: 0.19-0.50, p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Abnormal expression of lncRNAs are involved in the occurrence and development of glioma. Thus, weconducted a meta-analysis to clarify the prognostic value of lncRNAs in glioma integrally. Methods: Pubmed, Web of Science, Embase, Cochrane Library, Clinical Trial.gov and Trip database were searched. Haz ard ratio (HR) and 95% confidence intervals (CI) were calculated in the analysis of prognostic indicators. Odds ratio (OR)and 95%CI were applied to estimate the association between lncRNAs and clinicopathological features. Results: The expression level of lncRNA was significantly correlated with the OS rate of glioma patients (HR=1.29,95%CI: 1.03-1.61, p=0.03). The low expression of CASC2 (HR=0.42, 95%CI: 0.27-0.66, p=0.0001) showed a poor prog nosis of glioma patients. MALAT1 (HR=1.42, 95%CI: 0.38-5.29, p=0.60), HOTAIR (HR=1.70, 95%CI: 0.69-4.21, p=0.25) andTUSC7 (HR=1.81, 95%CI: 0.87-3.75, p=0.11) have no statistical significance for the prognosis of glioma patients. The highexpression of lncRNA was related to WHO staging (OR=0.31, 95%CI: 0.19-0.50, p

🔖

Cite This Article

CHEN, L., SUN, H., LIU, J., MA, X., TAN, L., YAN, Y., SHAO, S., LIU, R., MA, H., HUI, B., CHAI, L., REN, J. (2022). A Meta-Analysis of the Prognostic Value of AbnormallyExpressed lncRNAs and Correlation with ClinicopathologicalCharacteristics in Glioma. Eurasian Journal of Medicine and Oncology, Cilt: 5 - Sayı: 2, 144–156. https://ajindex.com/articles/509476

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Morlando M, Ballarino M, Fatica A, Bozzoni I. The role of long noncoding RNAs in the epigenetic control of gene expression. Chemmedchem 2014;9:505–10
  2. Peng Q, Du X. The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod Pathol 2013;26:155– 65
  3. Fan F, Zhu Z, Gao C, Liu Y, Wang B, Wang Z, et al. Prognostic value of LncRNAs in lung carcinoma: A meta-analysis. Oncotarget 2017;8:83292–305
  4. Chen J, Chen Y, Gu L, Li X, Gao Y, Lyu X, et al. LncRNAs act as prognostic and diagnostic biomarkers in renal cell carcinoma: A systematic review and meta-analysis. Oncotarget 2016;7:74325–36
  5. Lei L, Wang J, Zhang L, Chen Y, Yuan P, Liu D. Meta-analysis of the clinical value of abnormally expressed long non-coding RNAs for pancreatic cancer. Oncotarget 2017;8:89149–59
  6. Cui X, Xuan J, Wu X. The prognostic value of long non coding RNAs in cervical cancer: A meta-analysis. Oncotarget 2017;8:62470–7
  7. Wang J, Du S, Wang J, Fan W, Wang P, Zhang Z, et al. The prognostic value of abnormally expressed LncRNAs in colorectal cancer: A meta-analysis. Plos One 2017;12:e0179670
  8. Cao S, Wang Y, Li J, Lv M, Niu H, Tian Y. Tumor-suppressive function of long noncoding RNA malat1 in glioma cells by suppressing mir-155 expression and activating fbxw7 function. Am J Cancer Res 2016;6:2561–74
  9. Chen W, Xu XK, Li JL, Kong KK, Li H, Chen C, et al. Malat1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing mir203 and promoting thymidylate synthase expression. Oncotarget 2017;8:22783–99
  10. Ma KX, Wang HJ, Li XR, Li T, Su G, Yang P, et al. Long noncoding RNA malat1 associates with the malignant status and poor prognosis in glioma. Tumour Biol 2015;36:3355–9
  11. Wang R, Li Y, Zhu G, Tian B, Zeng W, Yang Y, et al. Long noncoding RNA CASC2 predicts the prognosis of glioma patients and functions as a suppressor for gliomas by suppressing Wnt/β-catenin signaling pathway. Neuropsychiatr Dis Treat 2017;13:1805–13
  12. Liao Y, Shen L, Zhao H, Liu Q, Fu J, Guo Y, et al. LncRNA CASC2 interacts with miR-181a to modulate glioma growth and resistance to TMZ through PTEN pathway. J Cell Biochem 2017;118:1889–99
  13. Serghiou S, Kyriakopoulou A, Ioannidis JP. Long noncoding RNAs as novel predictors of survival in human cancer: a systematic review and meta-analysis. Mol Cancer 2016;15:50
  14. Reon BJ, Anaya J, Zhang Y, Mandell J, Purow B, Abounader R, et al. Expression of lncRNAs in low-grade